Abstract 1087
Background
Several lines of evidence suggest that the gut microbiome represents a novel biomarker in the era of immuno-oncology. Therefore, the prospective collection of fecal samples is now routinely included in clinical trials and acts as a new challenge for research nurses. However, little is known about patient compliance in the collection process. The objective of this study was to assess enrolment and compliance rates for fecal sample collection.
Methods
Fecal samples were prospectively collected in two academic institutions, University of Montreal Hospital and Gustave Roussy Cancer Center, using the International Human Microbiome Standards SOP Version 3 in the following groups: (1) patients with advanced non-small cell lung cancer (NSCLC) amenable to immune checkpoint inhibitors and (2) patients with early-stage NSCLC or renal cell carcinoma (RCC) at a pre-operative stage. Informed and written consent were obtained by research nurses and patient baseline characteristics were collected. Upon consent, a white opaque polypropylene pot with an anaerobic generator bag was provided to the patient, along with a document to explain the self-collection technique. Enrolment (signing of consent) and compliance (returning the sample) rates were analysed using a Chi-squared method.
Results
A total of 267 patients were eligible for the study and 252 (94%) patients with a median age of 64 agreed to sign the consent form. The enrolment rate in the study reached 96% (175/183) in patients receiving immunotherapy compared to 92% (77/84) in patients with early stage cancers undergoing surgical resection who did not receive immunotherapy (p = 0.01). Overall patient compliance was 81% (204/252). Importantly, compliance was significantly higher in the pre-immunotherapy setting (94%, 164/175) versus the pre-operative group (52%, 40/77) (p = 0.01). Furthermore, regardless of the cancer stage, women (82% or 77 patients) were more compliant than men (80% or 127 patients) (p = 0.02).
Conclusions
New tools to increase compliance and assist patients in sample collection should be developed, especially for male patients diagnosed with early stage disease who are undergoing surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Bertrand Routy.
Funding
Montreal Cancer Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract